Jack Meehan
Stock Analyst at Barclays
(3.05)
# 1,120
Out of 5,182 analysts
128
Total ratings
69.51%
Success rate
21.33%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $275 → $290 | $259.57 | +11.72% | 17 | Oct 2, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $114.87 | +8.82% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $300.73 | -4.23% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $7.86 | +319.85% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $126.92 | +156.07% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $14.21 | +33.71% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $195.05 | -49.24% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $102.49 | +75.63% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $4.84 | +106.61% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $158.98 | +4.42% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $166.79 | -7.67% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $279.34 | +53.93% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $299.45 | +43.60% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $12.02 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $36.26 | +32.38% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,262.48 | -46.14% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $63.14 | -52.49% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $470.22 | -36.20% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $0.87 | +4,515.21% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275 → $290
Current: $259.57
Upside: +11.72%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $114.87
Upside: +8.82%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $300.73
Upside: -4.23%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $7.86
Upside: +319.85%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $126.92
Upside: +156.07%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $14.21
Upside: +33.71%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $195.05
Upside: -49.24%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $102.49
Upside: +75.63%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $4.84
Upside: +106.61%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $158.98
Upside: +4.42%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $166.79
Upside: -7.67%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $279.34
Upside: +53.93%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $299.45
Upside: +43.60%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $12.02
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $36.26
Upside: +32.38%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,262.48
Upside: -46.14%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $63.14
Upside: -52.49%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $470.22
Upside: -36.20%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $0.87
Upside: +4,515.21%